Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Deloitte
Dow
Express Scripts
Covington
Moodys
Novartis
McKinsey
QuintilesIMS

Generated: January 17, 2018

DrugPatentWatch Database Preview

JANTOVEN Drug Profile

« Back to Dashboard

Which patents cover Jantoven, and what generic alternatives are available?

Jantoven is a drug marketed by Usl Pharma and is included in one NDA.

The generic ingredient in JANTOVEN is warfarin sodium. There are twenty-two drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
Drug patent expirations by year for JANTOVEN
Pharmacology for JANTOVEN
Drug ClassVitamin K Antagonist
Mechanism of ActionVitamin K Inhibitors

US Patents and Regulatory Information for JANTOVEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-001 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-007 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-004 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-008 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-002 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-003 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-006 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-005 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Usl Pharma JANTOVEN warfarin sodium TABLET;ORAL 040416-009 Oct 2, 2003 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chubb
Novartis
Harvard Business School
Federal Trade Commission
Deloitte
Citi
Boehringer Ingelheim
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot